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ABSTRACT
Purpose To evaluate transcytosis of immunoglobulin G (IgG) by
the neonatal Fc receptor (FcRn) in adult primate intestine to
determine whether this is a means for oral delivery of monoclonal
antibodies (mAbs).
Methods Relative regional expression of FcRn and localization in
human intestinal mucosa by RT-PCR, ELISA & immunohisto-
chemistry. Transcytosis of full-length mAbs (sandwich ELISA-
based detection) across human intestinal segments mounted in
Ussing-type chambers, human intestinal (caco-2) cell monolayers
grown in transwells, and serum levels after regional intestinal
delivery in isoflurane-anesthetized cynomolgus monkeys.
Results In human intestine, there was an increasing proximal-distal
gradient of mucosal FcRn mRNA and protein expression. In
cynomolgus, serum mAb levels were greater after ileum-proximal
colon infusion than after administration to stomach or proximal small
intestine (1–5 mg/kg). Serum levels of wild-type mAb dosed into
ileum/proximal colon (2 mg/kg) were 124±104 ng/ml (n=3)
compared to 48±48 ng/ml (n=2) after a non-FcRn binding
variant. In vitro , mAb transcytosis in polarized caco-2 cell mono-
layers and was not enhanced by increased apical cell surface IgG
binding to FcRn. An unexpected finding in primate small intestine,
was intense FcRn expression in enteroendocrine cells
(chromagranin A, GLP-1 and GLP-2 containing).
Conclusions In adult primates, FcRn is expressed more highly in
distal intestinal epithelial cells. However, mAb delivery to that
region results in low serum levels, in part because apical surface
FcRn binding does not influence mAb transcytosis. High FcRn
expression in enteroendocrine cells could provide a novel means
to target mAbs for metabolic diseases after systemic
administration.
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INTRODUCTION
Monoclonal antibody (mAb) therapeutics are not adminis-
tered orally due to their degradation by digestive enzymes in
the intestinal lumen and low intestinal permeation, resulting
from their large molecular size and high polarity. However, in
perinatal mammals, intestinal transepithelial and transplacen-
tal transport of immunoglobulin G (IgG) is via the neonatal Fc
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receptor (FcRn; also Brambell receptor). This Fc receptor was
initially discovered in the neonatal rat intestine (1–4) and it
resembles the major histocompatibility complex class I anti-
gens in that it has a heavy chain transmembrane glycoprotein
associated with a light chain β2-microglobulin (5).
In the rodent intestinal epithelium, high levels of FcRn
expression and IgG transport are restricted to the suckling
period (6–8) during which time it is highly active, accounting
for ~80% of IgG uptake from the duodenum (9). In contrast, in
primates, FcRn is expressed in the intestine in villous
enterocytes throughout adult life (10,11). This has led to de-
cades of speculation that targeting FcRn could enable oral
delivery of mAbs in humans. To date, evaluation of human
FcRn-mediated IgG transcytosis has been limited to over-
expressing human FcRn epithelial cell lines or transgenic mice
(9,12,13). Rodent FcRn-mediated oral delivery has only been
demonstrated in suckling rat pups, for example, in a report that
oral delivery of a FSH-human Fc domain fusion molecule
resulted in systemic levels that retained functionality (14).
However, several factors combine to overestimate the apparent
IgG oral bioavailability in neonates, such as reduced proteolysis
of IgG by trypsin (15), increased endocytotic mechanisms in
neonatal enterocytes (16) and immature mucosal barriers until
after weaning (17). Thus, while it is useful mechanistically to
study neonatal rodent intestinal FcRn, this model would not be
predictive of oral bioavailability in adult humans. There are no
reports of in vivo assessment of FcRn distribution and mAb oral
bioavailability in the primate intestine, to our knowledge.
However, bronchiole delivery of an erythropoietin-Fc fusion
protein to the non-human primate airway resulted in systemic
bioavailability (18). Therefore, we rationalized that if bronchial
epithelial cells could transport mAb from apical to basolateral
in primates in vivo , an investigation into similar FcRn function-
ality in the adult primate intestine could support this potential
mechanism for oral delivery of mAbs.
To address this, we used mAbs with Fc mutations designed
to modulate binding to FcRn combined with a detection assay
to quantify the presence of transported full-length mAb direct-
ly. Fc mutations have been applied to IgG-based therapeutics
to exploit FcRn functions and selectively target tissues (19). For
example, amino acid replacements of residues in the CH2-3
region of Fc increase FcRn binding affinity and are useful to
increase its circulating serum half-life (19,20). Conversely, a
Fab that contains a polyethylene glycol moiety in place of an
Fc region is useful because it reduces transplacental transfer of
the molecule (21). Therefore, the present study used wild-type
(WT) mAb and engineered FcRn binding affinity variants
in vitro , in isolated human intestine and in vivo in cynomolgus
monkeys by direct intestinal delivery to assess whether effec-
tive FcRn-mediated transcytosis could contribute to intestinal
mAb uptake. In addition, regional FcRn expression and im-
munohistochemical localization was determined using an
anti-human FcRn polyclonal antibody.
These experiments illustrated regional intestinal epithelial
FcRn expression and demonstrated that some mAb apical-to-
basal transcytosis occurred, but could not address whether
apical surface FcRn engages mAb from the intestinal lumen.
Brambell’s original hypothesis is that IgG binds to FcRn in the
acidified conditions of the endosome and IgG is internalized
after pinocytosis (i.e. not necessarily after cell surface FcRn
binding). However, in human intestinal cells apical FcRn ex-
pression is noted (12,22) with increased FcRn expression in
apical endocytic pits after exposure to IgG (4). In addition, many
investigators incubate mAb in acidic pH to enhance FcRn cell
surface binding in vitro (11–13), even though intracellular FcRn
is more prevalent (11). If intestinal lumen exposure to mAb
results in FcRn binding on the apical surface of enterocytes,
then this would be an attractive mechanism to target for orally
delivered mAbs in humans. Therefore, the expression and con-
tribution of cell surface FcRn tomAb transcytosis was assessed in
endogenously FcRn-expressing human intestinal caco-2 cells.
MATERIALS AND METHODS
All animal studies were performed in accordance with the
Federal Animal Welfare Act and protocols were approved
by the Institutional Animal Care and Use Committee at
Janssen Pharmaceutical R&D, Biotechnology Center of
Excellence. Human intestinal tissue, which was not used for
transplant purposes, was transported and processed as soon as
possible after death. Donor tissue met the following qualifica-
tion criteria: male or female, ≤65 years of age, with no known
history of gastrointestinal disease or alcohol abuse, and having
accompanying demographics information.
Monoclonal Antibody Isotype and Engineered mAb
FcRn Binding Affinity
Human mAbs with mutations on IgG1 or IgG2 isotype were
generated in house. The complimentary determining regions
were to respiratory syncytial virus (RSV; also referred to as
B21M) on an IgG1 isotype or to an endogenous growth factor
on a 1gG2 isotype (M13 andM15). Variants of anti-RSV IgG1
WT were generated by mutating asparagine at position 434 to
alanine (23) or the histidine at position 435 to alanine (24,25)
and termed anti-RSV N434A and H435A, respectively. A
variant (termed M15 M428L) was generated by mutating a
methionine at position 428 to leucine (26). Their binding
affinities to FcRn were determined at pH 6.0, since FcRn is
localized in the acidified endosomes in intestinal epithelial cells
(11), which favors IgG-FcRn binding and protects the IgG
from lysosomal degradation. Binding at pH 7.4 was expected
to be negligible. Table I describes the binding affinities
to human FcRn or cynomolgus FcRn by Surface
Plasmon Resonance methodology (27), as described
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previously (9). A similar rank order of mAb variant affinity was
obtained for binding to both cyno and human FcRn at pH6.0
(Table I), with variants N434A andM428L showing increased
the affinity to FcRn compared to WT and loss of binding in
variant H435A.
FcRn Expression and mAb Transcytosis in Human
Intestine
Human donor intestines from a 24-year-old female Hispanic, a
47-year-old African American male and a 49-year-old African
American female were obtained shortly after death (due to
stroke/intracranial bleed). Intestinal mucosa was collected and
either snap frozen or added to 500 μl M-PER solution in lysis
tubes formRNA and protein expression, respectively. Full thick-
ness intestinal segments were fixed flat between biopsy sponges
in 10% neutral buffered formalin and paraffin imbedded.
mAb Transcytosis in Isolated Human Intestine
Muscle-stripped segments were rapidly mounted in Ussing-
type flux chambers and after several washes in Krebs-Ringer
bicarbonate (KRB) buffer at pH 7.4, incubated on the mucosal
side with atenolol, a control compound to determine perme-
ability, co-mixed with mAb at pH 6.5. Samples of serosal side
media (50% rat serum andKRB buffer at pH7.4) were assayed
by LC-MS/MS for atenolol, a paracellular permeability mark-
er, by standard analytical methods. Standards were prepared
by serial dilution into matrix matched to the mucosal side
(KRB buffer pH 6.0 in a six point concentration range of 5–
500 nM) and serosal side (KRB buffer pH 7.4: rat serum 1:1 v/
v, in a seven point concentration range of 5–5,000 nM) sam-
ples. Mucosal side aliquots were diluted 500-fold with KRB
buffer pH 6.0, but serosal side samples were not diluted.
Samples and standards were quenched in a 1:2 proportion
with acetonitrile, vortexed for 5 min, and then centrifuged at
13,000 rpm for 10 min. The supernatant was collected, diluted
1:3 with water, and analyzed by liquid chromatography.
Thermo Hypersil BDS C18 (30×2.0 mm i.d., 3 μm) was used
with guard column M.P. Buffer (25 mM ammonium formate
buffer, pH 3.5) at a flow rate of 300 μL/minute and aqueous
reservoir (90% water, 10% buffer) and organic Reservoir (90%
acetonitrile, 10% buffer) for a total run time of 3.5 min.
Analysis by mass spectrometer (PE SCIEX API 3000, multiple
reactionmonitoring) was for 10 μl samples using turbo ionspray
interface for 3.5 min duration. Based on the LC-MS
analysis of atenolol concentration on the mucosal and serosal
sides, the atenolol permeation calculated based on apparent
permeability coefficient, Papp=(δCr/δt)×Vr/(A×C0), was
confirmed to be within the expected range for all segments
up to 180 mins (Papp<7×10−6 cm/s in small intestine and<
10×10−6 cm/s for colon).
Detection of Full-Length mAb
Serosal samples were analyzed for intact mAb based on the
MesoScale Discovery (MSD) electrochemiluminescent for-
mat. For detection of full-length mAb, an anti-idiotypic anti-
body specific to the mAbs (M15 or anti-RSV) were labeled
with Sulfo-NHS-LC-Biotin and used as capture antibody on
streptavidin-coated MSD plates. A pan anti-human IgG1/
IgG2 antibody labeled with MSD Sulfo-TAG NHS Ester was
used as the detection antibody. Relative Luminescent Units
(RLU) were measured using a Sector Imager 6000 reader and
Discovery Workbench software (MSD). Acceptance criteria
were a minimum of two fold over background signal: noise
ratio for samples, and 70–130% recovery on spiked QC
duplicates. Based non-linear regression analysis of standard
curves (GraphPad Prism version 5), mAb unknown concen-
trations were back-calculated by extrapolation from the stan-
dard curve. The quantification range was determined to be
between 0.05 and 500 ng/ml.
Human FcRn Protein Expression
An FcRn ELISA on human donor mucosa was performed on
plates coated with affinity-purified goat anti-human FcRn
antibody (1.0 μg/ml, prepared in-house) and incubated in
rat anti-human FcRn antibody (5 μg/ml) and then alkaline
phosphatase conjugated goat anti-rat antibody at 1:10,000
(Jackson Immunoresearch; West Grove, PA, USA). Using a
standard curve (15.6 – 1,000 μg/ml BSA; Micro BCA
Table I mAb Binding Affinity to
Human and Cyno FcRn at pH 6.0
and pH7.4
* no observable binding up to
1.0 μM
mAb Name Isotype & Mutation Affinity to FcRn (KD in nM)
pH 6.0 pH 7.4
Cyno Human Cyno Human
Anti-RSV B21M IgG1 WT 447 520 * *
Anti-RSV B21M IgG1 N434A 109 134 * *
Anti-RSV B21M IgG1 H435A * * * *
Growth Factor M13 IgG2 WT 111 125 * *
Growth Factor M15 IgG2 M428L 58 50 * *
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Bradford Assay Kit, Thermoscientific; Rockford, IL) OD
values from duplicate samples were back-calculated and re-
ported as FcRn/mg of total protein.
Intestinal FcRn Immunohistochemistry
Paraffin-imbedded 5 μm sections were cut from full-thickness
intestine harvested from monkey and human donors, and
from human tissue bank (MTB-311 and MTB-316; Qualtek
Molecular Labs, Goleta, CA) and dried on glass slides (60°C).
Steam heat induced epitope recovery (SHIER) system was
used with pretreatment in the solutions in the capillary gap in
the upper chamber of a Black and Decker Steamer (28).
Sections were incubated in affinity purified rat anti-human
FcRn polyclonal antibody (generated in house) or rabbit anti-
human FcRn, (H-274, Santa Cruz Biotechnologies) or control
(non-immune) IgG then stained using Avidin Biotin Complex
immunohistochemistry (9). For colocalization of FcRn with
enteroendocrine (EE) hormones in human tissue, primary
antibodies were rabbit anti-human GLP-1 (7–37) and GLP-
2 (Phoenix Pharmaceuticals, Burlingame CA), anti-CCK-8
(Sigma, St Louis MO) and anti-Gastrin (Dako, Denmark)
using a secondary donkey anti-rabbit IgG (Alexa fluor-
555 at 1:500, Invitrogen, Grand Island, NY). Colocalization
of EE hormones with FcRn was by creating a sandwich of four
adjacent sections consisting of rat IgG negative control, anti-
human FcRn, anti-EE, and rabbit IgG negative control. FcRn
and EE-stained sections remain adjacent, separated by 5 μm.
Representative images using Koehler illumination were
obtained with an Olympus Microfire digital camera (M/N
S97809) attached to an Olympus BX60 microscope.
In rat pups under isoflurane surgical inhalation anesthesia a
midline laparotomy was performed and a 27 g needle was
placed directly into the duodenum, ileum and proximal colon,
approximately 1 cm distal to the cecum, as reported in detail
(9). After bolus intestinal dosing of anti-growth factor (1.0 mg/
kg diluted to 10 ml/kg in PBS) the needle was removed and a
small ligating clip placed to prevent any leakage into the
abdominal cavity. Blood (~200 μl) was collected at 5 and
90 min post-dosing from the retro-orbital venous plexus.
The serum was separated and frozen at −80°C until assayed,
as reported above. After euthanasia, small intestinal full thick-
ness tissue (~ 1 cm) from rat pups and mucosal scrapings from
their dams were snap frozen for mRNA analysis (below).
To determine differences in gastrointestinal regional mAb up-
take, eight monkeys (7 male and 1 female; weight 4.3–7.3 kg)
received mAb delivered to different regions of the GI tract (1–
5 mg/kg diluted in 10 mls PBS) as shown in Table II. In those
monkey receiving gastrointestinal dosing on more than one
occasion, mAbs were delivered minimally invasively by oral
gavage to the stomach (n =3; 2.5 mg/kg mAb) or by
videogastroscopy using a flexible pediatric endoscope
(Olympus GIF-XP160 Video Gastroscope; n=6; 1–5 mg/kg)
to the upper intestine, while monkeys were under isoflurane
surgical anesthesia. During videogastroscopy, duodenal muco-
sal biopsies were obtained using endoscopic cup biopsy forceps
that were fixed in 10%NBF used for FcRn immunohistochem-
istry. Blood draws were pre-administration, 5, 90 mins and 4,
24, and 48 hrs. post-endoscopy. In three monkeys femoral vein
bolus of 0.05 mg/kg anti-growth factor was administered with
blood draws from 1.5 to 504 h for determination of circulating
half-life of the higher FcRn binding affinity variant in primates.
The individual concentration-time profile was analyzed using
non-compartmental analysis (NCA) by Winnonlin (v5.2). The
terminal elimination rate constant (lz) was determined by least-
squared regression of log-linear transformed data of the termi-
nal phase. The half-life (t1/2) was estimated by natural log 2
times reciprocal lz.
Acute delivery of mAb in isoflurane-anesthetized animals
involved a midline laparotomy and direct infusion into intes-
tines through a 5-ml syringe with butterfly angiocatheter.
Following bolus administration in different intestinal regions
blood draws (pre-, 5 and 90 mins) and intestinal fluid (90 mins)
were taken prior to animals being euthanized. Resected intes-
tinal segments (post-mortem) full-thickness intestine and muco-
sal biopsies from proximal, mid and distal small intestine were
placed in 10% neutral buffered formalin for immunohisto-
chemistry (as described for human tissue above). The concen-
tration of mAb in intestinal fluid at termination (diluted 1:1 in
monkey serum containing protease inhibitor and centrifuged
3,500 rpm for 10mins) and in the serum was detected based on
theMSD electrochemiluminescent format (as described above).
The predicted blood volume for the monkey gender and
weight of cynomolgus macaques was estimated from graphs
reported in (29). Fractional uptake at 90 min after intestinal
dosing was calculated based on the concentration in the serum
for each animal that was converted into the amount in the total
blood compartment. The percentage mAb in serum of the
amount delivered into the intestines was considered the fraction-
al uptake into that compartment. However, at 90 mins the mAb
would be distributed in the GI mucosa, lamina propria, lymph
and within vascular endothelial cells and therefore factional
serum uptake does not take into account total tissue distribution.
Regional Intestinal FcRn mRNA Expression from Rat,
Monkey and Human
Mucosa from human donor, monkey and adult rat intestine
and full thickness segments from rat pups were homogenized
Intestinal mAb Uptake 911
Rat Intestinal mAb Uptake In Vivo
Cynomolgus Regional Gastrointestinal




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































912 Hornby et al.
for total RNA purification (RNeasy Mini Kits, QIAGEN,
Valencia, CA, USA). The RNA quality was confirmed
(RNA Nano chip, Agilent Technologies; Waldbronn,
Germany) using the Agilent RNA 6000 (Nano Reagents
Part I, Agilent Technologies; Vilnius, Lithuania) and run on
an Agilent 2100 bioanalyzer. The concentration was deter-
mined by A260 readings and 0.3–1 μg RNA from each
sample was reverse transcribed to cDNA (Applied
Biosystems; Carlsbad, CA, USA). Within a species, the same
amount of RNA was added to the cDNA setup.
TaqMan primers and probes (Applied Biosystems) for hu-
man and rat HPRT; human, rat, and rhesus GAPDH; hu-
man, rat, and rhesus FcRn were run in triplicate for RT-PCR.
The CT values generated from human and rat lysates were
normalized to human and rat GAPDH and HPRT, respec-
tively. For absolute quantification of the number of FcRn
molecules per ng RNA, a known amount of plasmids carrying
human FcRn genes were used to determine a standard curve
relating the number of molecules of FcRn to the CT value,
which was then used to extrapolate the number of FcRn
molecules in each lysate sample. The number of molecules
per ng RNA (20–50 ng depending on concentration) was
determined based upon the amount of cDNA. Absolute quan-
tification of cyno FcRn was not possible because only rhesus
FcRn was available for hybridization.
FcRn Cellular Localization and mAb Transcytosis
in Human Intestinal Cells
These experiments were designed to determine FcRn expres-
sion and role of surface versus intracellular FcRn binding to
mAb transcytosis in an endogenous FcRn expressing caco-2
cell line derived from colorectal adenocarcinomas.
Three methods were used to determine FcRn expression in
caco-2 cells grown to confluence in transwells for 14–21 days.
For flow cytometry, acutase dissociated cells were centrifuged
@ 1,800 rpm for 7 min at 4°C, washed and incubated (1×106
cells/well in 50 μl at 4°C for 45 min) in rat anti-human FcRn
polyclonal alone, or in the presence of unlabelled FcRn
(50 μg/ml), followed by a secondary antibody (7.5 μg/ml).
Controls included omission of the primary antibody and
isotype control (rat IgG 50 μg/ml). Cells were stained with
near-infra-red live/dead dye 0.25 μl in 50 μl of PBS
(Invitrogen). Plates were spun (1,300 rpm for 3 min at 4°C)
and samples resuspended in 400 μl of FACS buffer and run on
the LSR Fortessa. ForWestern blot, FcRn expression in whole
cell caco-2 lysates was determined in reduced 20 μl samples
containing equivalent protein (~15 μg) loaded per lane. These
were run on 4–12 SDS-PAGE, blotted onto nitrocellulose
membrane, and incubated in primary rabbit anti FcRn (M-
255; Santa Cruz, CA. 1 h at 1:300) then donkey anti rabbit
680 (Licor 1:3000). For FcRn immunofluorescence, cells were
fixed in situ in 4% paraformaldehyde and permeabilized with
0.5% Triton X-100. After addition of Image-iT® FX signal
enhancer (Invitrogen; Carlsbad, CA), cells were treated with
1X Blocking Buffer (Sigma-Aldrich; St. Louis, MO) before
exposure to rat anti-human FcRn. Immunoreactivity to pri-
mary antibody was detected with a FITC-conjugated donkey
anti-rat IgG secondary antibody (Jackson Immunoresearch,
West Grove, PA). Prolong GOLD antifade with DAPI
(Invitrogen) was added to wells prior to image capture using
a Nikon SMZ-1500 fluorescence dissecting microscope.
The cellular location of mAb was determined after incuba-
tion of caco-2 cells in either FcRn-mAb binding (pH 6.0 or
FcRn binding anti-RSV WT or N435A) or non-binding
(pH 7.4 or anti-RSV H435A) conditions. For quantification
of mAb binding affinity on the cell surface, caco-2 cells (1 × 104
or 2.5 × 104 cells per well for 2 h@RT) were allowed to attach
to the plate surface of MSDHigh Bind plates (MSD; Rockville,
MD). Plates were then blocked with 20% FBS (Life
Technologies) and 0.18% Sodium Azide (15 min RT) and
washed once with DPBS at pH 6.0 before incubation with
FcRn-binding variants (anti-RSV N434A or anti-RSV
H435A at pH 6.0; 90 min at 37°C). This was followed by
incubation with ruthenium-labeled goat anti-human IgG
F(ab')2 (1 μg/ml in DPBS at pH 6.0 for 1 h RT) and then
Tris-based Read Buffer T without surfactant was added to
wells immediately before measuring RLU, as described previ-
ously. Background subtracted RLU’s were used to calculate
mAb binding IC50 by variable slope non-linear regression
(GraphPad Prism 5.0).
For detection of mAb in cell lysates from caco-2 monolayers
grown in transwells, mAb (anti-RSV WT or H435A) were
incubated on apical side for 90 min at pH 6.0, then thoroughly
rinsed (3 times in cold PBS) and cells scraped into 250mlM-per
lysis buffer with protease inhibitors. Surface FcRn-dependent
apical-to-basolateral transcytosis was tested in caco-2 mono-
layers grown in transwells by apical incubation of cells ofWTor
H435A mAb at pH 6.0 or 7.4 for 90 mins. The mAb concen-
tration in cell lysates and on the basolateral side were deter-
mined by MSD format and back-calculation from standard
curves (0.005–500 ng/mL), as described in previous section.
RESULTS
FcRn Expression and mAb Transcytosis in Human
Donor Intestines
To determine regional intestinal differences in mAb
transcytosis, isolated muscle-stripped human intestinal seg-
ments (n=9 per region, 3 donors) were incubated on the
mucosal side with M15 (anti-growth factor with high FcRn
binding affinity; 20 and 200 μg/mL inKRB buffer at pH 6.5).
This resulted in a concentration-related increase in M15
detected at 180 mins in all small intestinal regions and
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proximal colon (Fig. 1a). However, mAb concentration de-
tected across the proximal colon tended to be slightly higher
(Fig. 1a). Differences in mAb detection on the basolateral side
were not due to tissue handling or permability since atenolol, a
low molecular weight low permeability compound co-mixed
with the mAb, had low apparent paracellular permeability
that was well within acceptance criteria for the presence of an
intact barrier function in these segments. FcRn protein ex-
pression in mucosal scrapings of the adjacent (non-incubated)
segments was higher in the proximal colon compared to the
lowest expressing region, which was the jejunum (Fig. 1b).
Similar to this, the molecules of FcRn mRNA detected in the
mucosa tended to be relatively higher in colon than jejunum
but varied between donors.When the FcRnmRNA expressed
per segment was plotted against mAb trancysosis for each
donor there appeared to be a correlation (Fig. 1c), although
high donor-to-donor variability was apparent.
FcRn immunoreactivity in full-thickness sections of same
human donor intestines was visualized in villous enterocytes of
small intestine (Fig. 2a, b; large arrowheads), as expected.
Qualitatively, FcRn immunostaining was similar in colonic
and small intestinal enterocytes from the same donor
(Fig. 2c, d; arrowheads). Unexpectedly, intense FcRn immu-
noreactivity was noted in a few cells located in the small
intestinal crypts and proximal colon from all donor intestines
(Fig. 2a, c; small arrows). These cells will be described later in
the “Results” section.
To translate the relative expression of FcRn mRNA in
human intestinal mucosa into some idea of transcytosis effi-
ciency, the absolute FcRn mRNA expression in four intestinal
regions was compared in adult human, adult rat, and suckling
rat pup (Fig. 3). These were selected because rat pup has high
FcRn expression with high FcRn transcytosis efficiency where-
as adult rat loses FcRn expression after weaning. Overall,
human intestinal FcRn mRNA (Fig. 3a) showed a gradient
of increasing expression from proximal to distal intestine. In
the jejunum/ileum, FcRnmRNA levels were~two-fold great-
er than in adult rat, and proximal colon was~ten-fold greater
(Fig. 3b). This contrasted with the rat pup intestine where the
highest FcRn mRNA was in the duodenum and jejunum (7,9)
and was~ten-fold greater than human proximal colon
(Fig. 3c). Consistent with the higher duodenal mRNA expres-
sion in rat pup, higher serum mAb levels were obtained in
isoflurane-anesthetized 2-week-old rat pups after direct duo-
denal dosing, compared to distal small intestine or proximal
colon administration (Fig. 3d). Thus, the regional efficiency of
mAb uptake reflected the decreasing gradient of FcRnmRNA
expression in rat pups. Overall, since the levels of FcRn
mRNA found in human were above adult rat intestine (no
FcRn mediated transport) and an increasing proximal-distal
gradient in FcRn expression levels was noted, mAb systemic
uptake after regional intestinal delivery was subsequently eval-
uated in adult primates.
FcRn Expression and In Vivo mAb Intestinal Uptake
to Serum in Cynomolgus
In vivo experiments were performed in nine cynomolgus mon-
keys that were dosed over a 7 month period (Table II).
Monkeys were dosed by oral gavage, proximal intestinal ad-
ministration by videogastroendoscopy, or by laparotomy
followed by direct surgical infusion through the intestinal wall
into the small intestine and proximal colon. Seven monkeys
had a repeat administration of anti-growth factor mAb. In


















































































Fig. 1 Human donor muscle-stripped intestinal segments (three segments in
each of four regions per donor for a total of n=9/region, mean ± SEM)
assessed for transcytosis and FcRn protein and mRNA expression. Segments
mounted in Ussing-type flux chambers were incubated on the mucosal-side
with M15 (20 and 200 μg/mL) and concentration-related low levels of full-
length mAb were detected on the serosal side after180 mins (a ). In adjacent
intestinal mucosal scrapings (b ), protein levels of FcRn (by ELISA) in proximal
colon were higher than in jejunum (P<0.05 by ANOVA and Newman-
Kreuls post-test). When FcRn mRNA/total mRNA was plotted against M15
mAb uptake for each donor (c ), there was an apparent correlation.
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cases where there was a third mAb administration, anti-RSV
was dosed instead (Table II) to reduce the likelihood of inter-
ference in mAb detection because of potential monkey anti-
idiotype antibodies to anti-growth factor in circulation.
The initial videogastroscopy dosing into duodenum/
jejunum (1–2 mg/kg; n=4) resulted in low but detectable
serum levels of anti-growth factor mAb in two monkeys as
early as 90 mins later (diamonds, Fig. 4e). In monkeys where
serum was collected up to 48 h after dosing, mAb levels
peaked at 24 hrs (circles, Fig. 4e). In two different monkeys,
videogastroscopy delivery into the duodenum/proximal jeju-
num with higher dose (5 mg/kg M15, n=2), did not result in
higher serum levels (Table II). Oral gavage into the stomach
(2.5 mg/kg, n=3) resulted in no detectable serum levels (e.g. at
24 h; Table II) up to 96 hrs. In these three monkeys subse-
quent IV administration of the M15 (FcRn higher binding
affinity anti-growth factor mAb 0.05 mg/kg) was performed
to determine circulating half-life (Table II). The individual
serum levels (total of eight time points from 1.5 to 504 h in
Table II) are reported for all three monkeys. The individual
concentration-time profile (1.5–504 h post dosing) was
analyzed using non-compartmental analysis by Winnonlin
(v5.2), which resulted in a circulating half-life~14 days.
Therefore, the serum concentration up to at least 48 h after
intestinal administration should reflect intestinal uptake and
not be confounded by loss of mAb from circulation.
A dose of mAb acutely (5 mg/kg, n=2) into five regions
throughout the small intestine and proximal colon (pan-
intestinal delivery), resulted in the higher detectable mAb
serum levels at 90 mins (3 and 14 ng/ml) than proximal
intestine administration. FcRn immunostaining was noted in
enterocytes from a mucosal biopsy from duodenum/jejunum
transition (Fig. 4a), and post-mortem full-thickness proximal
colon (Fig. 4c) of the same monkey. However, small intestinal
FcRn mucosal distribution tended to be patchy (arrows in
Fig. 4a, b), whereas colonic staining was more evenly distrib-
uted and diffuse (arrows in Fig. 4c, d). The high background
and histological damage in the colon segment (Fig. 4d) was
due to a delay in fixation after removal in the surgical suite,
but differential intensity of enterocyte FcRn–staining and
control was still evident. Together with the initial small intes-
tinal dosing results, the FcRn immunostaining suggested that
a
c d
bAnti-FcRn IgG controlFig. 2 FcRn immunoreactivity infixed and paraffin-imbedded 5 μm
sections of donor ileum (a ) and
colon (c ) confirms the ELISA data
shown in Fig. 1b. FcRn-
immunostaining in intestinal
enterocytes (arrowheads ) was
above background staining
observed in adjacent control rat IgG
stained sections (b , d ).
Unexpectedly, intense FcRn
immunostaining was visualized in a
few cells within the small intestinal
crypts and proximal colon, which
were not observed in controls
(small arrows ).
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the distal small intestine or proximal colon might be where
most intact mAb uptake was occurring.
We tested this directly by dosing WT mAb and H435A
variant into distal ileum/proximal colon after laparotomy in
five monkeys, and the individual mAb concentration in serum
and gastrointestinal fluid are illustrated (Fig. 4f). High individ-
ual variability was noted in the concentration of full-length
mAb in distal small intestine and proximal colon fluid (Fig. 4f),
and very low intestinal mAb concentrations in two monkeys
(one in each group) was associated with the lowest serum
levels. Figure 4f illustrates that, compared to previous intesti-
nal dosing, the highest detectable serum levels were achieved
in 2 of 3 monkeys dosed with B21M WT (124±104 ng/mL;
2 mg/kg, n=3 mean ± SEM) and 1 of 2 monkeys dosed with
the non-FcRn binding variant H435A (48±48 ng/mL mean
± SEM; 2 mg/kg, n=2). However, there was no statistically
significant difference between the serum uptake of WT and
H435A variant at 90 min post-dosing. Serum fractional up-
take was calculated based for the predicted blood volume by
gender and weight of cynomolgus macaques (29). Based on
monkey weight taken just prior to dosing, the fractional
uptake into serum of the dose administered into intestines
was 0.32% and 0.15%, respectively. Samples of jugular blood
that were taken close to the entry of the thoracic duct resulted
in slighly higher levels of mAb than femoral bleeds for each
monkey (Fig. 4f), suggesting that uptake through the lymphat-
ic system was occuring in these animals.
The in vivo data were consistent with distal small intestine/
colon uptake of mAb but inconclusive as to whether FcRn
binding influences mAb intestinal uptake in primates, despite
the presence of FcRn in enterocytes. We reasoned that if mAb
on apical surface was internalized by pinocytosis rather than
being FcRn-dependent, then this would limit mAb uptake
in vivo . To test this, several different experimental approaches
in caco-2 cells were used to determine FcRn cell surface
engagement and mAb transcytosis in vitro (Fig. 5). Western
blots of caco-2 cell lysates confirmed intense anti-FcRn bands
at a molecular weight ~42 kD similar to recombinant human
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Fig. 3 FcRn mRNA expression
quantified to total mRNA in human
donor mucosa (a ) where n=3;
adult rat mucosa (b ) where n=5,
and suckling rat pup full-thickness
sections (c) where n=4 (raw data
were log transformed since
underlying assumptions of equal
variance and normal distribution
shape were more tenable). (d ) In
suckling rat pups (n=6), mAb
serum levels were greater after
administration of M15 into the
proximal than to the distal small
intestine and showed a functional
proximal- distal gradient paralleling
FcRn mRNA expression. P<0.05
by 1-way ANOVA and Bonferroni’s
post-tests.
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In Vitro FcRn Surface Expression and Transcytosis
in Human Intestinal Enterocytes
FcRn, as expected (11)(data not shown). This was supported
by intense cytoplasmic FcRn immunofluorescence, although
heterogeneity of FcRn-expressing and non-FcRn-expressing
cell populations was noted (Fig. 5a). By flow cytometry, sur-
face FcRn expression occurred in 62% of the total population
of dissociated cells (Fig. 5b). The % of population is shown
(Fig. 5b) rather than Mean Fluorescence Units (MFI) because
of the apparent FcRn-expressing heterogeneity of caco-2 cells.
Cell surface mAb binding with an IC50 of 1.5 μg/ml was
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Fig. 4 Cynomolgus monkey intestine FcRn immunostaining and mAb levels after dosing. Duodenal/jejunal mucosal biopsy illustrated patchy FcRn immuno-
staining in villous enterocytes (a , arrowheads ), which was not observed in adjacent control rat IgG section (b ). In the same monkey, full-thickness proximal colon
has FcRn-immunostaining evenly distributed throughout (c , arrowheads ). Artifactual and non-specific staining (d ) is due to post-mortem tissue handling. In 3 out of
4 isoflurane-anesthetized cynomolgus anti-growth factor mAb dosed into the proximal small intestine (1–2mg/kg), resulted in low femoral vein serum levels post-
dosing at 90 mins and up to 48 h (e ). Dosing mAb acutely into the ileum and proximal colon (2 mg/kg anti-RSV H435A, n=2; and WT, n=3) resulted in much
higher femoral vein serum levels at 90 mins in 3 out of 5 monkeys (f). In these 3 monkeys, mAb concentrations were slightly higher from jugular vein (taken near
thoracic duct). Very low intestinal fluid mAb concentrations in two monkeys were associated with very low serum mAb levels. ND=Not Done.
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a low signal (RLU) that suggests a low FcRn expression on the
cell surface (Fig. 5c). Negligable specific binding was detected
on the cell surface for H435A, a non-FcRn binding variant
(Fig. 5c).
It should be noted that flow cytometry and cell surface
binding were performed on dissociated (ie not polarized) cells.
In polarized caco-2 cell monolayers, apical incubation of mAb
at concentrations around the surface FcRn binding IC50, failed
to demonstrate surfacemAb transcytosis after 90mins (Fig. 5d).
However, apical incubation of mAb at 100 fold greater con-
centration than the surface FcRn-binding IC50, resulted in
more WT than non-FcRn binding variant detected in lysed
cells (Fig. 5e). Thus, mAb was internalized at this higher
concentration and endosomal IgG-FcRn binding occurred.
Apical-to-basoloateral transcytosis of WT by caco-2 cell mono-
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Fig. 5 FcRn expression and mAb localization in caco-2 cells. (a ) Immunofluorescence of FcRn and nuclear DAPI illustrates intense intracellular FcRn in
heterogeneous cells. (b ) By flow cytometry, ~ 60% of dissociated caco-2 cells had cell surface FcRn expression that was competitively abolished using an equal
concentration of soluble unlabeled FcRn. (c ) A detectable signal for surface binding of an FcRn-binding affinity mAb (N434A 0.0001 – 5.0 μg/ml) in dissociated
caco-2 cell resulted in an IC50=1.5 μg/ml (0.01 μM). A non-FcRn binding mAb (H435A) had no measurable surface binding (n=3 per group) (d) In polarized
caco-2 cell monolayers apical to basolateral mAb transcytosis did not occur after incubation at apical concentrations close to the surface FcRn-binding IC50 (1.5 μg/
ml) for either WTor H435A (n=3 per group). (e ) In polarized caco-2 cell monolayers grown in transwells, apical incubation of mAb concentrations well above
the surface FcRn-binding IC50 resulted in intracellular detection of more WT than non-FcRn binding variant in lysed cells at the highest concentration (n=4 per
group; P<0.05 by 2-way ANOVA and Bonferroni’s post-test). (f) Similar apical-to-basolateral transcytosis of WT by caco-2 cell monolayers grown in transwells
incubated at higher WTconcentrations at either apical pH 6.0 or pH 7.4 (n=6 per group).
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were done at pH 6.0 or pH 7.4. All these data suggest that
apical surface FcRn expression is low and surface FcRn-IgG
binding was inconsequential to overall transcytosis. Based on
these findings, mAb present in the intestinal lumen that had
enhanced affinity to FcRn would not be expected to have faster
entry into endocytotic pits in a receptor-mediated fashion.
Novel Observation of FcRn Immunostaining in Primate
EnteroEndocrine Cells
Intense FcRn immunostaining in human small intestine crypt
cells was visualized in banked human intestinal samples. Because
this had not been reported previously we compared the FcRn
localization by the in-house anti-FcRn to a commercially avail-
able anti-FcRn (H-274, Santa Cruz, CA) in adjacent sections
(Fig. 6a, b). Sections were 5 um apart which resulted in some
variation in cell presence and visibility between sections; how-
ever, two apparent matches of commercial and in-house anti-
FcRn stained cells were noted in this example (Fig. 6a, b arrows).
High background staining in the case of the purchased anti-
FcRn hampered detection of specific FcRn immunostaining.
Due to the FcRn localization in crypt cells and their mor-
phological appearance, human small intestinal tissue was thin-
sectioned for FcRn colocalization studies using chromagranin A
(Fig. 6c,d), Glucagon-Like Peptide (GLP)-1 (Fig. 6e,f), andGLP-
2 (Fig. 6g,h) immunostaining in the adjacent section. Overall,
the prevalence of FcRn-immunoreactive cells was lower than
chromagranin A stained cells, which suggested that FcRn was
colocalized sub-populations of enteroendocrine cells (Fig. 6c,d
arrows). FcRn-immunostaining in cells overlapped more exten-
sively with GLP-1 and GLP-2 immunoreactive cells. However,
EE hormones other than justGLP1 andGLP-2were likely to be
colocalized with FcRn throughout the small intestine, colon and
stomach. For example, gastrin, cholecystokinin (CCK) immu-
nostained cells were extensively colocalized with FcRn in the
stomach (data not shown). Comprehensive immunoflourescence
colocalization would be necessary to determine the prevalence
and identity enteroendocrine cells that expressed FcRn.
To determine the prevalence of FcRn-immunostaining in
cells from a variety of sources, colon samples of human neona-
tal (n=3), cynomolgus (n=2) andmouse (n=4) were compared.
In general, neonatal colon crypt cells had a greater frequency
and intensity of FcRn staining than adult, as illustrated in the
example (Fig. 7a, b). Cynomolgus colon had a low prevalance,
but similar localization of FcRn immunostained cells (Fig 7c, d).
However, no FcRn specific -immunoreactivity was apparent in
C57b6 mice intestine compared to rat IgG negative control, as
illustrated in proximal colon (Fig. 7e, f).
DISCUSSION
This study addresses how previous evidence for FcRn-
mediated IgG transcytosis in epithelial cells (12,13,30) might
translate into mAb oral bioavailability in primates. Our novel














Fig. 6 Crypt cell FcRn immunostaining in human small intestine using in house anti-FcRn (top row) was colocalized (arrows ) with commercially available anti-FcRn
(b ), chromagranin A (d), GLP-1 (f), and GLP-2 (h) immunostaining in the adjacent section that were 5 μm apart. A high background-signal using anti-FcRn (H-
274, Santa Cruz; b ) hampered detection of specific FcRn immunostained cells, though two apparent matches to in-house anti-FcRn stained cells are indicated (a ,
b arrows ). FcRn-immunoreactive cells (c) were less prevalent than chromagranin A stained cells (e ), with somematches that suggest a colocalized sub-population
(arrows ). FcRn-immunostaining (e , g ) overlaps extensively in GLP-1 (f) and GLP-2 (h) immunoreactive cells.
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increasing proximal-distal gradient of FcRn expression, with
highest FcRn expression in the proximal colon. Consistent
with this, greater levels of mAb transfer across the intestinal
wall were noted in both isolated human intestine proximal
colon and after acute ileum/proximal colon administration in
adult cynomolgus in vivo . However the fractional uptake of
full-length mAb (~ 0.3%) was still relatively low. In addi-
tion, variability in intestinal mAb proteolysis contributed to
variable serum levels resulting in no group differences in
serum levels of WT mAb compared to non-FcRn bind-
ing affinity mAb. These points will be discussed in the
context of the known literature on intestinal FcRn with
respect to the likelihood of oral delivery of mAb by this
mechanism.
Previously, no difference in the regional expression of FcRn
in human fetal intestine was noted by western blot (11),
whereas a decreasing FcRn proximal-distal has been reported
by several groups in neonatal rat pups (7,9). This present study
is the first to demonstrate an increasing FcRn proximal-distal
gradient of expression in adult human intestine, in contrast to
neonatal rodents. However, it is hard to translate expression
levels into functionality. Therefore, we compared FcRn
mRNA/ng total RNA expression using probes 100 bp in
length estimate total cDNA across species. This approximated
the FcRn expression in human proximal colon to be ~10 fold
lower than neonatal rat pup duodenum and~10 fold higher
than adult rat intestine. Since adult rat intestine (8,9) did not
express sufficient intestinal FcRn for mAb transport, this could
represent a ‘floor’ of mRNA that does not translate into
protein function. The fact that human proximal colon FcRn
mRNA expression is above that floor level and only 10 fold
lower that neonatal rat duodenum where IgG is actively
transported (8,9) suggests that FcRnmediated transport might
be expected.
The 0.3% fractional mAb uptake obtained from adult
primate ileum/colon is much less than the ~20% fractional
uptake from duodenum of suckling rat pups (7,9), which is
consistent with the latter being a mechanistic model of FcRn
transcytosis but not predictive of oral biovailability in adult
primate. The 0.3% fractional uptake from ileum/colon deliv-
ery is markedly greater than uptake from the primate upper
gastrointestinal tract, and had not been reported previously.
Even though uptake is low it is possible that, with a long
enough circulating half-life and a sufficiently potent mAb,
therapeutic levels could be achieved after repeated (daily)
dosing with a mAb formulated for specific ileo-colonic release
from an enteric coated capsule. One issue in the monkey
intestinal dosing study was the high variability in systemic
uptake, which was a reflection of the extent of mAb proteolysis
in the intestinal contents. In twomonkeys, one dosed withWT
and one dosed with H435A, there were very low mAb levels
detected in the luminal contents, and in both individuals
extremely low serum levels were detected. This means that
additional engineering or formulation to protect the mAb
from proteolysis should improve bioavailability. That addition-
al optimization is needed is to be expected, similar to a report
where inhaled bioavailability of a bivalent erythropoietin-Fc
fusion molecule in adult primates was still relatively low, maybe
due to steric hindrance, compared to a ‘monomeric’
erythropoietin-Fc fusion protein (18). Optimization of biophys-
ical properties for colonic site-specific delivery could enhance
mAb oral bioavailability.
Ninetyminutes after dosing into the ileum/proximal colon,
mAb levels in the jugular vein, taken near the entrance of the
thoracic duct, were slightly higher in each monkey compared
the systemic circulation. This is noteworthy because large
molecules within the lamina propria interstitium enter the
lymphatic lacteals through an incomplete basal lamina and
lack of tight junctions (31) and empty via the thoracic duct into
junction of the left subclavian and jugular vein. We previously











Fig. 7 Crypt cell FcRn immunostaining and adjacent control rat IgG in
banked colon from stillborn (a , b ), cynomolgus monkey (c ,d ) and C57b6
mice (e ,f). The intensity numbers of FcRn immunostained cells were the
highest in neonatal human. Adult cynomolgus was similar to adult human. No
FcRn reactivity was apparent in C57b6 mice throughout the intestine com-
pared to rat IgG negative control and illustrated in proximal colon.
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circulation via the lymphatics rather than mesenteric drainage
into the hepatic portal vein (9), thus avoiding a ‘first pass’
effect. The present data in monkeys suggest that the absorp-
tion of mAb into the circulation occurs through the same
route and alsomitigates concern that the serum levels detected
were due to surgical damage.
In spite of an improvement in uptake (0.3%) after acute
ileum/proximal colon delivery of WTmAb compared to oral
gavage (0%), it was inconclusive whether FcRn binding affin-
ity affected transcytosis in vivo . In enterocytes, FcRn is primar-
ily located in the endosomes (4,11) but there are a number of
reports that FcRn is also located on the apical surface in
human intestinal epithelial cell lines (12,22) and as well as
receptors on the brush borders of neonatal enterocytes (4).
Therefore, we designed pharmacological experiments using
caco-2 cells in vitro to determine if apical surface FcRn expres-
sion contributed to mAb transcytosis, in addition to the inter-
nalization and endosomal FcRn-mAb interactions that were
reported previously in caco-2 cells (32). Both flow cytometry
and immunohistochemistry showed that a population of caco-
2 cells expressed FcRn on the cell surface. In confirmation of
this FcRn surface binding affinity of WTmAb was 1.5 μg/ml,
whereas H435A had no binding affinity. However, in caco-2
cells grown in transwells, cell surface FcRn binding of IgG on
the apical side around the IC50 concentrations did not influ-
ence overall mAb transcytosis to the basolateral side. Since
neither apical surface pH nor mAb FcRn affinity affected
internalization or transcytosis obtained at saturating concen-
trations (≥10 fold greater than the surface binding affinity), this
suggests that a non-receptor mediated process was involved in
mAb apical internalization. Although apical acidic pH condi-
tions to enhance transcytosis are documented in human FcRn
transfected epithelial cells in vitro (13,33), it is mostly accepted
that, once inside the cell, the acidic pH in endosomes enables
FcRn-mAb binding and transcytosis. In previous reports, sur-
face receptor saturating concentrations (e.g. 200 μg/ml IgG;
(32)) resulted in internalization, similar to this report. Thus
non-receptor mediated endocytosis is a mechanism of mAb
uptake in both adult, as well as neonatal (16), enterocytes.
Non-receptor mediated endocytosis of mAb that is slow and
rate limiting, prior to FcRn binding within the endosome and
transcytosis, could limit uptake of mAb from the intestinal
lumen observed in monkeys in vivo .
An unexpected finding of the present study was the identi-
fication of sub-population of EE cells that express FcRn with
CCK8, gastrin in the stomach and GLP-1 and GLP-2 in the
small intestine. FcRn expression was noted previously in crypt
cells in small intestinal tissue from patients undergoing gastric
by-pass (12) but were not previously identified as being
enteroendocrine cells specifically. Interestingly, extensive
colocalization was noted in the intestine where FcRn was
expressed in L-cells (i.e. those that express GLP-1 and GLP-
2) and in the stomach, where FcRn was expressed in G cells
(i.e. those that express gastrin) and CCK cells. Thus, FcRn was
not limited in expression to a specific cell type (i.e. incretin cells
versus CCK expressing cells) nor to EE cells in a specific region
(i.e. intestine versus stomach). FcRn expression may be a fun-
damental property of these cells that reveals new functionali-
ties for FcRn related to endocrine-immune interactions and
currently unkown. In terms of delivery though, the novel
finding of FcRn expression in these cells provides opportuni-
ties for targeting of mAb to enteroendocrine cells. Fc engi-
neering to enhance FcRn internalization of mAb for recycling
rather than transcytosis may be useful in this regard and has
been reported previously (34). However, additional research
would have to be done to determine is this will become a
viable strategy for metabolic disease therapeutics.
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